OR WAIT 15 SECS
Sandoz has signed an agreement with Shionogi for the commercialization rights of Rizmoic (naldemedine) within specific key European markets.
Sandoz has revealed in an April 11, 2019 press statement that it has signed an agreement with Shionogi for the commercialization rights of Rizmoic (naldemedine) within specific key European markets.
Under the terms of the agreement, Sandoz will be responsible for commercializing Rizmoic in Germany, the United Kingdom, and the Netherlands. Additionally, it will have the right of first refusal for some other European markets, which were not disclosed. Shionogi will continue to be responsible for the manufacture and development of Rizmoic.
Rizmoic was granted marketing authorization by the European Union on Feb. 22, 2019. It is a once-daily 200-microgram oral tablet indicated for the treatment of adult patients with opioid induced constipation (OIC) who have previously been treated with a laxative.
“Our purpose at Sandoz is to pioneer access by focusing increasingly on differentiated, value-added therapeutics that can make a real difference when it comes to meeting unmet medical needs,” said Francesco Balestrieri, Sandoz CEO a.i. “This agreement represents a significant step forward for that strategy and for patients in Europe, reinforcing our long-term commitment to building a leading anti-pain franchise and complementing our portfolio dedicated to minimizing the side-effects of opioid use.”